NCT00673010

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Completed Phase 1 Last updated 9 October 2025

What this trial tests

Phase 1 trial testing 131 I-iodine (131-I), 124 I-iodine (124-I) in Thyroid Cancer in 20 participants. Completed in 2 October 2025.

Timeline

7 March 2005

Primary endpoint
2 October 2025

2 October 2025

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	7 March 2005
Primary completion	2 October 2025
Estimated completion	2 October 2025
Sites	1 location across United States

Drugs / interventions tested

• 131 I-iodine (131-I), 124 I-iodine (124-I)

Conditions studied

• Thyroid Cancer — all drugs for Thyroid Cancer →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer cells that have spread to other parts of the body. In many cases this treatment destroys the metastatic cells. However, in some patients it does not appear to work completely. This study is designed to use a slightly different form of radioactive iodine (called 124-I) which can precisely predict the amount of radiation that each metastatic lesion will receive.

124-I was developed at Memorial Sloan-Kettering in the 1950s and has been used here and at many other medical centers around the world for diagnostic studies. It has been found to be very safe and effective at finding metastatic lesions. The high resolution of newer PET scanners now allows us to carefully determine how much radiation each metastatic lesion will receive. If 124-I can accurately predict which patients will not respond to 131-I treatments we can then avoid exposing those patients to unnecessary radiation. For the rest of the patients we can custom tailor the 131-I dose to destroy the metastatic lesions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
   Barca C, Griessinger CM, Faust A, Depke D, et al · · 2021 · cited 42× · PMID 35056071 · DOI 10.3390/ph15010013
2. Modulation of sodium iodide symporter in thyroid cancer.
   Lakshmanan A, Scarberry D, Shen DH, Jhiang SM. · · 2014 · cited 21× · PMID 25234361 · DOI 10.1007/s12672-014-0203-0